Physician profile
Bernardo Stein
NPI 1952391518
$6,451.61
in general payments reported to CMS, 2019-2025
20 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $539 · 2020: $218 · 2021: $993 · 2022: $2,036 · 2023: $2,132 · 2024: $384 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,500 · Food and Beverage: $1,139 · Education: $26.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,500.00 |
| Food and Beverage | $1,139.47 |
| Education | $26.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,408.77 | 2020-2025 | Avvigo Guidance System, Lux-Dx Insertable Cardiac Monitor, Eluvia |
| Astrazeneca Pharmaceuticals LP | $1,670.73 | 2019-2025 | Farxiga |
| Abiomed | $367.47 | 2020-2025 | Impella |
| Shockwave Medical, INC | $162.57 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic, INC. | $142.07 | 2023 | Reveal Linq |
| Amgen INC. | $133.04 | 2019-2025 | Repatha, Repatha |
| Inspire Medical Systems, INC. | $121.58 | 2024 | Inspire |
| Penumbra, INC. | $100.00 | 2019 | |
| Abbott Laboratories | $56.71 | 2019-2023 | Diamondback Peripheral |
| Pfizer INC. | $55.67 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $51.99 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $49.78 | 2019-2024 | Camzyos |
| Chiesi USA, INC. | $23.96 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $20.48 | 2019 | |
| Cardiva Medical, INC. | $17.70 | 2025 | Cardiva Vascade 5f Vcs |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $17.03 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.69 | 2019 | |
| Allergan, INC. | $13.23 | 2019 | |
| Medtronic Vascular, INC. | $12.64 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $10.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernardo Stein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.